Contrary to the CDC on the Mutating H1N1 Virus: Lakewood - Amedex Developing Broad Spectrum Drug

Contrary to the CDC denial that the H1N1 virus is mutating, Lakewood-Amdex is developing a broad spectrum influenza drug.

Steve Parkinson, L-A's President and Chief Executive Officer, commented, "We had intended to develop our broadly applicable influ-RNA product to treat seasonal flu and as an emergency stockpile product in the event of a further outbreak of avian influenza, but due to the escalating global H1N1 pandemic and now the report of this virus having been isolated from turkeys in Chile, we feel it is critical to have a product that can target multiple strains of influenza and is useable year after year."